0NF1 Stock Chart & Stats
€0.11
>-€0.01(-8.33%)
―
--
Day’s Range― - ―
52-Week Range€0.05 - €1.81
Previous CloseN/A
VolumeN/A
Average Volume (3M)113.00
Market Cap
€6.17M
Enterprise Value€33.31
Total Cash (Recent Filing)N/A
Total Debt (Recent Filing)N/A
Price to Earnings (P/E)<0.1
Beta-4.15
Next Earnings
Nov 17, 2026EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)N/A
Shares Outstanding58,548,050
10 Day Avg. Volume117
30 Day Avg. Volume113
Financial Highlights & Ratios
PEG RatioN/A
Price to Book (P/B)N/A
Price to Sales (P/S)N/A
P/FCF RatioN/A
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Mydecine Innovations Group News
0NF1 FAQ
What was Mydecine Innovations Group’s price range in the past 12 months?
Mydecine Innovations Group lowest stock price was €0.05 and its highest was €1.81 in the past 12 months.
What is Mydecine Innovations Group’s market cap?
Mydecine Innovations Group’s market cap is €6.17M.
When is Mydecine Innovations Group’s upcoming earnings report date?
Mydecine Innovations Group’s upcoming earnings report date is Nov 17, 2026 which is in 81 days.
How were Mydecine Innovations Group’s earnings last quarter?
Currently, no data Available
Is Mydecine Innovations Group overvalued?
According to Wall Street analysts Mydecine Innovations Group’s price is currently Undervalued.
Does Mydecine Innovations Group pay dividends?
Mydecine Innovations Group does not currently pay dividends.
What is Mydecine Innovations Group’s EPS estimate?
Mydecine Innovations Group’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Mydecine Innovations Group have?
Mydecine Innovations Group has 58,548,050 shares outstanding.
What happened to Mydecine Innovations Group’s price movement after its last earnings report?
Currently, no data Available
Which hedge fund is a major shareholder of Mydecine Innovations Group?
Currently, no hedge funds are holding shares in DE:0NF1
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
Mydecine Innovations Group
Mydecine Innovations Group Inc is a biopharma and life sciences company. It is committed to the research, development, and acceptance of alternative nature-sourced medicine for mainstream use. Reinforcing Mydecine's commitment to mental health solutions is underpinned by the company's three main focuses: Clinical Trials focusing on Veterans, EMS, and First Responders with a PTSD indication; Research and Development building a robust portfolio of intellectual property around drug discovery and unique delivery mechanisms with relevant use patents and future patent applications and Modern technology utilizing for better clinical trial management and mental health wellbeing.